Dr. Teachey is an Associate Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and a pediatric hematologist and oncologist at The Children’s Hospital of Philadelphia. He has dedicated his career to the investigation of childhood malignant and non-malignant disorders of lymphoid cells. His primary area of research is in acute lymphoblastic leukemia (ALL) with focus on subtypes of ALL with poor outcome. He studies novel therapies in his laboratory using preclinical models and has translated many of those therapies into the clinic. He is the PI on multiple local, national, and international ALL clinical trials and often performs the correlative studies for those trials in his lab. He is a member of the ALL Executive Disease Committee in the Children’s Oncology Group and is Chair of ALL biology. Dr. Teachey also studies immune dysregulation and lymphoproliferative disorders including Autoimmune Lymphoproliferative Syndrome (ALPS). He discovered that mTOR signaling is dysregulated in ALPS and that targeting mTOR with sirolimus is an effective therapy. Sirolimus is now the standard of care treatment for ALPS, transforming the prognosis for this rare disease. His interest in immune dysregulation has impacted ALL through investigation of the biology of cytokine release syndrome (CRS) after chimeric antigen receptor T cell therapy. He made the initial observation that CRS clinically resembles hemophagocytic lymphohistiocytosis (HLH) and confirmed this in the lab. Moreover, he suggested the use of the IL6 inhibitor tocilizumab for the treatment CRS after CAR T cell therapy after the first child treated became critically ill, based on the use of this class of agents for lymphoproliferative disorders. Tocilizumab was recently FDA approved for this indication. Dr. Teachey’s laboratory has been funded by the NIH and multiple foundations including Cures Within Reach, the American Cancer Society, and the Leukemia and Lymphoma Society.
David T. Teachey, MD